Outset Medical (NASDAQ:OM) Stock Rating Lowered by Wall Street Zen

Outset Medical (NASDAQ:OM) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Several other equities analysts also recently issued reports on the stock. BTIG Research cut their price objective on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Royal Bank Of Canada restated a “sector perform” rating and issued a $7.00 price objective on shares of Outset Medical in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Friday, March 27th. Finally, Stifel Nicolaus decreased their target price on Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Outset Medical Stock Down 2.8%

NASDAQ OM opened at $4.20 on Friday. The firm has a market capitalization of $76.90 million, a price-to-earnings ratio of -0.62 and a beta of 1.97. Outset Medical has a 52 week low of $3.00 and a 52 week high of $21.98. The company has a quick ratio of 5.40, a current ratio of 6.67 and a debt-to-equity ratio of 0.76. The company has a fifty day moving average of $3.75 and a two-hundred day moving average of $6.52.

Insiders Place Their Bets

In related news, EVP Marc Nash sold 5,375 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $27,520.00. Following the completion of the sale, the executive vice president directly owned 42,785 shares of the company’s stock, valued at approximately $219,059.20. This trade represents a 11.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Leslie Trigg sold 11,794 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $60,385.28. Following the sale, the chief executive officer directly owned 107,823 shares of the company’s stock, valued at $552,053.76. The trade was a 9.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 38,783 shares of company stock valued at $183,958 in the last three months. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Outset Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of OM. Los Angeles Capital Management LLC purchased a new position in Outset Medical during the 4th quarter valued at about $29,000. Legal & General Group Plc purchased a new position in shares of Outset Medical in the 2nd quarter valued at about $34,000. BNP Paribas Financial Markets raised its position in shares of Outset Medical by 7,013.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after acquiring an additional 2,034 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Outset Medical during the 4th quarter worth about $46,000. Finally, HRT Financial LP acquired a new stake in shares of Outset Medical during the 4th quarter worth about $58,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.